113 related articles for article (PubMed ID: 26402072)
1. Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds.
Duits FH; Hernandez-Guillamon M; Montaner J; Goos JD; Montañola A; Wattjes MP; Barkhof F; Scheltens P; Teunissen CE; van der Flier WM
J Alzheimers Dis; 2015; 48(3):711-20. PubMed ID: 26402072
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment.
Shams S; Granberg T; Martola J; Li X; Shams M; Fereshtehnejad SM; Cavallin L; Aspelin P; Kristoffersen-Wiberg M; Wahlund LO
J Cereb Blood Flow Metab; 2016 Mar; 36(3):621-8. PubMed ID: 26661151
[TBL] [Abstract][Full Text] [Related]
3. Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment.
Shams S; Granberg T; Martola J; Charidimou A; Li X; Shams M; Fereshtehnejad SM; Cavallin L; Aspelin P; Wiberg-Kristoffersen M; Wahlund LO
J Cereb Blood Flow Metab; 2017 Mar; 37(3):1006-1013. PubMed ID: 27178426
[TBL] [Abstract][Full Text] [Related]
4. Validation of biomarkers in subcortical ischaemic vascular disease of the Binswanger type: approach to targeted treatment trials.
Rosenberg GA; Prestopnik J; Adair JC; Huisa BN; Knoefel J; Caprihan A; Gasparovic C; Thompson J; Erhardt EB; Schrader R
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1324-30. PubMed ID: 25618903
[TBL] [Abstract][Full Text] [Related]
5. Expression Profiles of Matrix Metalloproteinases and Their Inhibitors in Nasal Polyps.
Duan C; Yu X; Feng X; Shi L; Wang D
J Inflamm Res; 2024; 17():29-39. PubMed ID: 38193041
[TBL] [Abstract][Full Text] [Related]
6. Altered cerebrovascular-CSF coupling in Alzheimer's Disease measured by functional near-infrared spectroscopy.
Ferdinando H; Moradi S; Korhonen V; Kiviniemi V; Myllylä T
Sci Rep; 2023 Dec; 13(1):22364. PubMed ID: 38102188
[TBL] [Abstract][Full Text] [Related]
7. Differences in metalloproteinases and their tissue inhibitors in the cerebrospinal fluid are associated with delirium.
Aksnes M; Schibstad MH; Chaudhry FA; Neerland BE; Caplan G; Saltvedt I; Eldholm RS; Myrstad M; Edwin TH; Persson K; Idland AV; Pollmann CT; Olsen RB; Wyller TB; Zetterberg H; Cunningham E; Watne LO
Commun Med (Lond); 2024 Jun; 4(1):124. PubMed ID: 38937571
[TBL] [Abstract][Full Text] [Related]
8. Astrocytic-derived vascular remodeling factors are independently associated with blood brain barrier permeability in Alzheimer's disease.
Bernocchi F; Bonomi CG; Assogna M; Moreschini A; Mercuri NB; Koch G; Martorana A; Motta C
Neurobiol Aging; 2024 May; 141():66-73. PubMed ID: 38823205
[TBL] [Abstract][Full Text] [Related]
9. The Link Between Matrix Metalloproteinases and Alzheimer's Disease Pathophysiology.
Radosinska D; Radosinska J
Mol Neurobiol; 2024 Jun; ():. PubMed ID: 38935232
[TBL] [Abstract][Full Text] [Related]
10. Breast-to-brain metastasis is exacerbated with chemotherapy through blood-cerebrospinal fluid barrier and induces Alzheimer's-like pathology.
Saatian B; Deshpande K; Herrera R; Sedighi S; Eisenbarth R; Iyer M; Das D; Julian A; Martirosian V; Lowman A; LaViolette P; Remsik J; Boire A; Sankey E; Fecci PE; Shiroishi MS; Chow F; Hurth K; Neman J
J Neurosci Res; 2023 Dec; 101(12):1900-1913. PubMed ID: 37787045
[TBL] [Abstract][Full Text] [Related]
11. Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease.
Hussain AA; Lee Y; Zhang JJ; Francis PT; Marshall J
J Neurodegener Dis; 2017; 2017():4810232. PubMed ID: 28197357
[No Abstract] [Full Text] [Related]
12. Natural Marine and Terrestrial Compounds as Modulators of Matrix Metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer's Disease.
Ciccone L; Vandooren J; Nencetti S; Orlandini E
Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33498927
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of matrix metalloproteinases 2 and 9 accompanied with neurogenesis following collagen glycosaminoglycan matrix implantation after surgical brain injury.
Hsu WC; Yu CH; Kung WM; Huang KF
Neural Regen Res; 2018 Jun; 13(6):1007-1012. PubMed ID: 29926827
[TBL] [Abstract][Full Text] [Related]
14. Rosacea as a potential risk factor for dementia.
Abdi P; Haq Z; Diaz MJ; Maibach HI; Ogunyemi B
Int J Dermatol; 2024 Jun; ():. PubMed ID: 38887091
[No Abstract] [Full Text] [Related]
15. Abnormal Expression and Distribution of MMP2 at Initial Stages of Alzheimer's Disease-Related Pathology.
Terni B; Ferrer I
J Alzheimers Dis; 2015; 46(2):461-9. PubMed ID: 26402409
[TBL] [Abstract][Full Text] [Related]
16. Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia.
Weekman EM; Wilcock DM
J Alzheimers Dis; 2016; 49(4):893-903. PubMed ID: 26599057
[TBL] [Abstract][Full Text] [Related]
17. The cytoskeleton in Alzheimer disease.
Terry RD
J Neural Transm Suppl; 1998; 53():141-5. PubMed ID: 9700652
[TBL] [Abstract][Full Text] [Related]
18. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice.
Castellano JM; Mosher KI; Abbey RJ; McBride AA; James ML; Berdnik D; Shen JC; Zou B; Xie XS; Tingle M; Hinkson IV; Angst MS; Wyss-Coray T
Nature; 2017 Apr; 544(7651):488-492. PubMed ID: 28424512
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
20. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
